Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Immune Therapy Can Control Fertility in Mammals

04.04.2011
Technique Could Prevent Pregnancy in Pets, Human Use Is Also Envisioned

Researchers at Weill Cornell Medical College have shown that it is possible to immunize mammals to control fertility. They say their technique could possibly be used on other mammals -- including humans -- because fertility hormones and their receptors are species-non-specific and are similar in both females and males. For pets, the technique could be an alternative to castration and adverse effects of hormone administration.

In the Feb. 24 online issue of Genetic Engineering and Biotechnology Journal, the researchers say their newly synthesized novel chimeric genes produce bi-functional recombinant proteins that are antigenic. The antibodies can tamp down production of progesterone in females and testosterone in males. The most immediate use of this technique might be to control fertility in dogs and cats or other mammals in need of population control, says the study's lead investigator, Dr. Brij B. Saxena, the Harold and Percy Uris Professor of Reproductive Biology at Weill Cornell Medical College.

After extensive preclinical testing for the efficacy, safety and reversibility in animals, the immune therapy might be possible in humans as a treatment for androgen excess syndromes as well as an immunological method to control fertility, adds Dr. Saxena.

The new chimeric gene was engineered by Dr. Saxena and his Weill Cornell colleagues, Dr. Meirong Hao and Dr. Premila Rathnam, and then inserted into insect cells to produce recombinant bi-functional protein. Immunity against fertility can be provided by the production of a bi-functional antibody by active or passive immunization using the recombinant protein.

This new gene contains DNA sequences from two natural genes that are integral to fertility in mammals. One portion is the extracellular domain (ECD) of the ligand (hormone) binding region of the human lutropin/human chorionic gonadotropin receptor (ECD-hLH-R), which is present in the ovaries and testes. The other component is the unique C-terminal peptide of the human chorionic gonadotropin â-subunit (hCG â-CTP).

Key to development of this new chimeric gene and recombinant protein is the researchers' finding that the hLH-R and hCG-â-CTP recombinant proteins are antigenic -- meaning that they can produce an immune response in the body, and produce bifunctional antibodies with dual effect. The antibodies are able to block the hormone binding to the receptor and thus suppress the signal to produce ovarian hormones, specifically progesterone. The second component of the antibody specific to hCG â-CTP would neutralize the hCG-like material produced by the fertilized egg prior to or at the time of implantation. This would lead to lack of stimulation to promote progesterone production by the corpus luteum, resulting in the lack of proliferation of endometrial growth that is vital for the implantation of the fertilized egg -- thus preventing pregnancy.

The scientists are now working on methods to upscale the production of recombinant chimeric protein to be tested as antigens in dogs and cats.

The study was funded by Concept-II, New York, NY.

Weill Cornell Medical College
Weill Cornell Medical College, Cornell University's medical school located in New York City, is committed to excellence in research, teaching, patient care and the advancement of the art and science of medicine, locally, nationally and globally. Physicians and scientists of Weill Cornell Medical College are engaged in cutting-edge research from bench to bedside, aimed at unlocking mysteries of the human body in health and sickness and toward developing new treatments and prevention strategies. In its commitment to global health and education, Weill Cornell has a strong presence in places such as Qatar, Tanzania, Haiti, Brazil, Austria and Turkey. Through the historic Weill Cornell Medical College in Qatar, the Medical College is the first in the U.S. to offer its M.D. degree overseas. Weill Cornell is the birthplace of many medical advances -- including the development of the Pap test for cervical cancer, the synthesis of penicillin, the first successful embryo-biopsy pregnancy and birth in the U.S., the first clinical trial of gene therapy for Parkinson's disease, and most recently, the world's first successful use of deep brain stimulation to treat a minimally conscious brain-injured patient. Weill Cornell Medical College is affiliated with NewYork-Presbyterian Hospital, where its faculty provides comprehensive patient care at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. The Medical College is also affiliated with the Methodist Hospital in Houston. For more information, visit weill.cornell.edu.

Andrew Klein | Newswise Science News
Further information:
http://www.cornell.edu

More articles from Life Sciences:

nachricht Cancer diagnosis: no more needles?
25.05.2018 | Christian-Albrechts-Universität zu Kiel

nachricht Less is more? Gene switch for healthy aging found
25.05.2018 | Leibniz-Institut für Alternsforschung - Fritz-Lipmann-Institut e.V. (FLI)

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Powerful IT security for the car of the future – research alliance develops new approaches

The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.

Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...

Im Focus: Molecular switch will facilitate the development of pioneering electro-optical devices

A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.

The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...

Im Focus: LZH showcases laser material processing of tomorrow at the LASYS 2018

At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.

At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...

Im Focus: Self-illuminating pixels for a new display generation

There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?

At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

In focus: Climate adapted plants

25.05.2018 | Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

 
Latest News

In focus: Climate adapted plants

25.05.2018 | Event News

Flow probes from the 3D printer

25.05.2018 | Machine Engineering

Less is more? Gene switch for healthy aging found

25.05.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>